Recent MASH treatments include weight loss-dependent peptide-based incretin therapies targeting glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptides, as well as weight loss-independent approaches such as FGF21 analogs (which increase adiponectin levels) and thyroid hormone receptor beta agonists like Resmetirom [66,67,68]. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatohepatitis.